Aurora SpineASAPF -1.49%39 EV-to-EBITDA is 25.48 as of Jul. 07, 2026. GuruFocus rates ASAPF with a GF Score™ of 39/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Aurora Spine ranks worse than 75.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aurora Spine's enterprise value is $16.31 Mil.
Aurora Spine's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.64 Mil. Therefore, Aurora Spine's EV-to-EBITDA for today is 25.48.
The historical rank and industry rank for Aurora Spine's EV-to-EBITDA or its related term are showing as below:
ASAPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.18 Med: -6.37 Max: 677.71
Current: 25.48
During the past 13 years, the highest EV-to-EBITDA of Aurora Spine was 677.71. The lowest was -155.18. And the median was -6.37.
ASAPF's EV-to-EBITDA is ranked worse than 75.98% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.385
vs ASAPF: 25.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aurora Spine's PE Ratio (TTM) for today is calculated as:
Aurora Spine's share price for today is $0.165.
Aurora Spine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aurora Spine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aurora Spine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Spine EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aurora Spine's EV-to-EBITDA falls into.
Aurora Spine's current Enterprise Value is $16.31 Mil.
Aurora Spine's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurora Spine (ASAPF) has a EV-to-EBITDA of 25.48 as of Jul. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aurora Spine. According to the industry distribution chart, Aurora Spine ranks #389 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 76%.
Is Aurora Spine's EV-to-EBITDA too high?
Aurora Spine's current EV-to-EBITDA is 25.48. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.39. Aurora Spine's value of 25.48 is 77.1% above this industry median. Based on the distribution chart, Aurora Spine ranks #389 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aurora Spine has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurora Spine's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aurora Spine ranks #389 out of 512 companies for EV-to-EBITDA. This places Aurora Spine in the lower half of its industry. The industry median EV-to-EBITDA is 14.39. Aurora Spine's value of 25.48 is 77.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.39, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Spine's current EV-to-EBITDA of 25.48 is 77.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aurora Spine. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Spine's current EV-to-EBITDA is 25.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Spine stock overvalued right now?
Based on GuruFocus' analysis, Aurora Spine (ASAPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.17 — trading 21.4% below its estimated fair value. The current EV-to-EBITDA is 25.48 and 77.1% above the Medical Devices & Instruments industry median of 14.39. Aurora Spine's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aurora Spine (ASAPF), the current EV-to-EBITDA is 25.48 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Spine (ASAPF) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Spine stock appears to be undervalued.
The current stock price of $0.17 is trading 21.4% below its estimated GF Value™ of $0.21.
GuruFocus considers Aurora Spine to be Modestly Undervalued.
Key valuation signals for ASAPF:
EV-to-EBITDA: 25.48
GF Value™: $0.21 vs. price of $0.17 (21.4% below fair value)
Industry Position: 77.1% above the Medical Devices & Instruments median (#389 of 512)
No single metric tells the full story. See the ASAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Spine Corp is engaged in the development, manufacture, and sale of minimally invasive, interspinous fusion systems and devices. These 510K and patent protected medical devices improve patient outcomes in the area of spine and sacroiliac joint surgical procedures. The company is focused on bringing new solutions to the spinal implant market through a series of minimally invasive, regenerative spinal implant technologies.
39GF Score
Get the complete analysis for ASAPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASAPF has been successfully added to your 
